



YOUR VISION IS OUR VISION™

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

September 18, 2023

Regulated Information

Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a first transparency notification on September 14, 2023, from Atlas Special Opportunities, LLC indicating that as of September 7, 2023, it held 106,332,703 shares of the then outstanding 2,551,311,977 shares, and therefore crossed above the threshold (3%) by virtue of the acquisition of voting securities. See Annex 1.

Oxurion received a second transparency notification on September 14, 2023, from Atlas Special Opportunities, LLC indicating that as of September 11, 2023, it held 69,155,581 shares of the then outstanding 2,551,311,977 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 2.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com</p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com</p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway mtconway@conwaycommsir.com</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights +

4) Notification by

A person that notifies alone +

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

07/09/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

2,551,311,977

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	0	106,332,703	0	4.17%	0.00%
TOTAL		106,332,703	0	4.17%	0.00%

Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

Sign Envelope ID: F7C777CB-716E-4D6F-B96B-2E84246E5775

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	106,332,703	4.17%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again voting rights as of (DD/MM/YYYY)

13) Additional information

On 7 September 2023 (with settlement date on 07/09/2023), Atlas Special Opportunities LLC converted 106,332,703 shares in Oxurion NV, as a result of which its shareholding increased to 106,332,703 shares (= 4.17%).

Done at New York

On 13/09/2023 (DD/MM/YYYY)

Name & capacity Lawrence Cutler, proxyholder

Signature *Lawrence Cutler*
09070936F244F3...

ANNEX 2

1) Status of the notification

Final

2) Issuer

Name OXJURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

-
+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

11/09/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

2,551,311,977

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	106,332,703	69,155,581	0	2.71%	0.00%
TOTAL		69,155,581	0	2.71%	0.00%

+

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

ocuSign Envelope ID: 0BB02BE6-CFBA-42BA-A978-C67F87A73818

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Holders of equivalent financial instruments						
TOTAL				0	0.00%	

+

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	69,155,581	2.71%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 7 September 2023 (with settlement date on 11/09/2023), Atlas Special Opportunities LLC sold 3,189,981 shares in Oxurion NV, as a result of which its shareholding decreased to 103,142,722 shares (= 4.04%). On 8 September 2023 (with settlement date on 12/09/2023), Atlas Special Opportunities LLC sold 11,358,856 shares in Oxurion NV, as a result of which its shareholding decreased to 91,744,866 shares (= 3.60%). On 11 September 2023 (with settlement date on 13/09/2023), Atlas Special Opportunities LLC sold 22,589,285 shares in Oxurion NV, as a result of which its shareholding decreased to 69,155,581 shares (= 2.71%)

Done at New York
On 13/09/2023 (DD/MM/YYYY)
Name & capacity Patrick Vance

DocuSigned by:
Signature Patrick Vance
5534B237B29544C...

Attachments

- [EN](#)
- [NL](#)